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AbstrAct 
The evolution of cellular pathology as a specialty has 
always been driven by technological developments 
and the clinical relevance of incorporating novel 
investigations into diagnostic practice. In recent years, 
the molecular characterisation of cancer has become of 
crucial relevance in patient treatment both for predictive 
testing and subclassification of certain tumours. Much 
of this has become possible due to the availability of 
next-generation sequencing technologies and the whole-
genome sequencing of tumours is now being rolled 
out into clinical practice in England via the 100 000 
Genome Project. The effective integration of cellular 
pathology reporting and genomic characterisation 
is crucial to ensure the morphological and genomic 
data are interpreted in the relevant context, though 
despite this, in many UK centres molecular testing is 
entirely detached from cellular pathology departments. 
The CM-Path initiative recognises there is a genomics 
knowledge and skills gap within cellular pathology that 
needs to be bridged through an upskilling of the current 
workforce and a redesign of pathology training. Bridging 
this gap will allow the development of an integrated 
’morphomolecular pathology’ specialty, which can 
maintain the relevance of cellular pathology at the centre 
of cancer patient management and allow the pathology 
community to continue to be a major influence in 
cancer discovery as well as playing a driving role in the 
delivery of precision medicine approaches. Here, several 
alternative models of pathology training, designed to 
address this challenge, are presented and appraised.
HistoricAl perspective of pAtHology: 
from An Autopsy science to A clinicAl 
science And A pillAr of reseArcH
The subject of pathology has been in evolution for 
over 2000 years, with progress made following 
waves of intellectual and technological advance-
ment. Early pathological understanding arose from 
the clinical descriptions of infections, inflammation 
and tumours first described by Hippocrates. Renais-
sance-era physicians and anatomists developed this 
understanding by describing gross pathological 
appearances seen through human dissection, and 
later Thomas Hodgkin was the first physician to 
define pathology by the microscopic appearances in 
human tissue, including the disease that now bears 
his name.
The extensive work of Rudolf Virchow, by many 
regarded as the greatest figure in the history of 
pathology, in describing and categorising human 
disease by cellular appearances layed the basis 
for the development of pathology as both a clin-
ical discipline and a modern science. In the late 
19th and early 20th centuries, teachers in morbid 
anatomy were found in medical schools throughout 
Europe representing the early ‘academic patholo-
gists’. Meanwhile, the clinical practice of ‘surgical 
pathology’ was beginning to be performed by physi-
cians and surgeons who used microscopic findings 
for clinical diagnosis. By the mid-20th century, these 
roles were consolidated as histopathology became 
recognised as a medical diagnostic discipline in its 
own right, one based on light microscopy, and with 
a strong academic ethos.1 2 Many names have been 
applied to the discipline of identifying the shape 
and form of cells and their spatial arrangement in 
healthy and pathological tissue and cell samples: 
Tissue Pathology, Cellular Pathology, Anatomic 
Pathology, Histopathology, Surgical Pathology and 
Cytopathology. All of these will be synonymous 
from now for the purpose of this document.
twenty-first century pAtHology: A 
morpHomoleculAr discipline?
In 1998, 45 years after the discovery of the DNA 
helix, the director of the National Cancer Institute 
challenged the scientific community to ‘harness 
the power of comprehensive molecular analysis 
technologies to make the classification of tumors 
vastly more informative’ and to change ‘the basis of 
tumor classification from morphological to molec-
ular characteristics’.3 Almost 20 years later, to what 
extent has this challenge been met?
Traditional pathology training has taught us to 
recognise and distinguish a myriad of pathological 
entities based on their macroscopic and microscopic 
morphological appearances. Complex diagnoses 
are founded on years of collective experience and 
an element of subjectivity. This is in contrast with 
molecular diagnostic methods, which are heavily 
technology driven and produce objective and quan-
titative data. Immunohistochemistry (IHC) sits 
somewhere between the two.
While IHC has been adopted into routine prac-
tice and pathology training, in many institutions 
‘traditional’ morphological pathology and ‘new 
molecular’ pathology laboratories exist in parallel, 
with little interaction. A notable exception to this 
is the work of the Specialist Integrated Haemato-
logical Malignancy Diagnostic Service (SIHMDS) 
in the UK. SIHMDS services combine elements 
of laboratory haematology, histopathology, flow 
cytometry, cytogenetics and molecular medicine 
prior to the production of a finalised integrated 
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report, which permits internal validation and crosschecking. The 
development of this model has not been without its difficulties: 
centralisation of services, co-location of several laboratories and 
information technology and computing infrastructure. Cellular 
pathology has much to learn, both from the successes and diffi-
culties that SIHMDS has experienced.4–6
estAblisHed moleculAr testing bAsed on tissues or 
cells
There are currently a number of tissue-based molecular tests used 
in routine diagnostic practice, although the exposure of indi-
vidual pathologists will be dependent on their area of practice, 
as in some subspecialties, molecular diagnostics has progressed 
more rapidly than in others.7 Some examples of frequently used 
molecular tests are summarised in table 1.
As our understanding of cancer biology progresses and new 
technologies develop, extension of these single-gene tests or 
low-target tests has the potential to completely reshape the field 
of tissue-based and cell-based molecular testing.8 For example, 
next-generation sequencing is beginning to show its full poten-
tial for diagnostic and therapeutic applications, particularly for 
the reclassification of diagnosis, therapeutic decision-making 
beyond the classic organ-specific treatment options and the 
detection of standard-of-care mutations.
IHC already has an established role in the histopathological 
taxonomy of diseases, with disease-specific ‘patterns of immu-
nohistochemical expression’ now a standard component of a 
pathologist’s diagnostic acumen. In recent decades, new uses 
have been postulated for some of these immunohistochemical 
biomarkers. For instance, the presence (or absence) of expression 
of a protein may be perceived as evidence of an inherited disease. 
In the field of cancer immunology, the assessment of markers of 
adaptive immunity (eg, CD3, CD4, CD8) and immune check-
points (eg, PD-1, PD-L1, OX-40, LAG3, TIM3) show promise 
as prognostic and predictive indicators. Indeed, in the era of 
personalised medicine, immunohistochemical expression may 
dictate a certain therapeutic intervention.9 10
molecular classification of cancer
With the notable exceptions of haematological malignancies 
and more recently brain tumours, the mainstay of cancer classi-
fication is morphology. However, large-scale genomic profiling 
studies have demonstrated the level of tumour diversity at a 
genomic level: genomic and transcriptomic analysis of breast 
cancer identified 10 ‘integrative subtypes’ with prognostic 
and therapeutic implications,11 and similar approaches in 
other tumours have indicated important additive information 
from genomic profiling.12–14 Ongoing national whole-genome 
sequencing (WGS) initiatives, such as the 100,000 Genome 
Project in the UK and Genome British Columbia in Canada, are 
integrating high-throughput genomic profiling of tumours into 
routine healthcare services. With plans already underway for the 
introduction of WGS to clinical laboratories, the advent of truly 
integrated morphomolecular reporting for cancer is imminent. 
As well as requiring expertise in the validation, interpretation 
and integration of molecular and morphological analysis, the not 
inconsiderable challenges associated with these genomic projects 
have highlighted the critical importance of sample integrity. 
While morphology is relatively forgiving to the vagaries of vari-
able tissue fixation, the integrity and validity of genomic analysis 
are heavily reliant on optimal and consistent sample handling. 
As the curators of tissue specimens, therefore, there is a strong 
case for ensuring that pathologists are equipped with the neces-
sary knowledge and skills to be leaders in the development of 
protocols for tissue-based genomic analysis and to oversee their 
implementation and use in a diagnostic setting.15
improved biomarker discovery and validation
High-throughput genomic profiling makes possible rapid and 
comprehensive analysis of cancer tissues even from small biopsy 
samples. Predictive (diagnostic) biomarkers can be used to match 
patients with targeted therapies. Prognostic markers can be inte-
grated into existing clinical staging systems for improved patient 
stratification. However, in spite of the large number of cred-
ible biomarkers identified in basic research studies, relatively 
few have been validated and accepted for routine clinical use. 
The steps to the translation of biomarkers into clinical use are 
summarised in figure 1.17 As many of the barriers are related to 
the way we deal with samples, technology or study design, this 
reinforces the importance of upskilling the pathology workforce, 
most of whom will be involved in such studies to some degree, in 
the limitations of molecular pathology methods, optimum spec-
imen processing and requirements for biomarker validation.
table 1 Established tissue-based molecular tests (adapted from 
Flynn et al25)
diagnostic therapeutic genetic
Lymphoma translocation detection KRAS/NRAS mutation testing MSI testing










ER, PR and HER2 protein 
expression
HER2 amplification
CNS, central nervous system; MMR, mismatch repair; MSI, microsatellite instability.
figure 1 Steps to adoption of a new biomarker for clinical use. 
Frequent barriers to progressing through these steps include inadequate 
technology, flaws in research design including use of an irrelevant study 
population, underpowering and inappropriate statistical analysis and 
impracticality or expense of the assay (as discussed by Kern).21
group.bmj.com on November 29, 2017 - Published by http://jcp.bmj.com/Downloaded from 
3Moore DA, et al. J Clin Pathol 2017;0:1–6. doi:10.1136/jclinpath-2017-204821
review
tumour heterogeneity and tumour evolution
The level of intratumour and intertumour heterogeneity16 17 
and the existence of tumour evolution18 including divergence 
of metastatic lesions from the primary tumour, all present chal-
lenges to understanding the biology of and ultimately to the 
successful long-term management of cancer. A gap analysis 
conducted by the charity Breast Cancer Now19 identified the 
lack of knowledge of metastatic disease, its evolution and inter-
action with the metastatic microenvironment as critical blocks in 
the improvement of patient outcomes. The panel emphasised the 
importance of systematic longitudinal biobanking of matched 
primary and metastatic samples, but also highlighted the unri-
valled value of the autopsy for tissue retrieval and global tumour 
analysis. Indeed, such initiatives in the UK and USA are leading 
to the re-emergence of the hospital autopsy to accelerate cancer 
research, and this places pathology at the forefront of discovery 
in this cutting-edge field.
embrAcing genomics: tHe expAnding role of 
pAtHology
The impact of molecular technologies on patient assessment, 
diagnosis and management means the role of the pathologist 
will expand and evolve. Apart from traditional morphological 
assessment of tissues and cells, and accompanying molecular 
tests, pathology is at the interface between biomarker validation, 
biomarker adoption and diagnostics.
influencing therapeutic decisions
Pathologists have a key role in the integration of molecular 
medicine into therapeutic pathways through their influence in 
biomarker translation, clinical trials and clinical data systems.20
Much of the large failure rate in the lack of clinical applicability 
of biomarker studies is in the fact that validation and biomarker 
adoption are suboptimally executed.21 22 Knowledge of when a 
new or alternative biomarker is needed, how to design and power 
such studies, which technology should support their clinical 
delivery and how to take a biomarker through European Medi-
cines Agency/Food and Drug Administration approval and National 
Health Service/National Institute for Health and Care Excellence 
adoption requires substantial, expert pathology knowledge.
Pathologists supporting clinical trials in local hospitals, and 
leading the pathology for multicentre clinical trials, require 
knowledge of the design and governance of trials, familiarity with 
laboratory protocols and an understanding of the analytical and 
biobanking aspects of trial management. This has relevance for both 
trials requiring patient stratification (close to a diagnostic activity) 
and those aiming to discover new determinants of response.
The management of pathological information in the context 
of LIMS (laboratory information management systems) and its 
integration in the context of hospital information systems will 
improve the quality of the diagnostic service. Equally, the use of 
this information for research purposes, within the requirements 
of anonymity, confidentiality and ethical approval, will facilitate 
hospital-based discovery.
clinical and scientific innovation
The development of digital pathology, pathology bioinformatics 
and biobanking represent critical areas of pathology activity in 
scientific discovery. Digital pathology and the adoption of image 
analysis have grown rapidly in the last few years due to advances 
in software, hardware and computer processing capacity, as 
well as the increasing importance of tissue-based research for 
biomarker discovery and stratified medicine. Digital pathology 
and image analysis have important roles across the drug/
companion diagnostic development pipeline and in molecular 
pathology studies, tissue microarray (TMA) analysis, biobanking 
and molecular profiling of tissue. Integrating digital image anal-
ysis data with epidemiological, clinical and genomic data will 
help maximise the potential of tissue samples in delivering 
personalised medicine.23
The analysis and management of large genomics data will be 
at the heart of the delivery of the promise of modern genomic 
medicine. Effective integration of morphology with the ample 
available genomic information will determine the value of 
pathology in the future.
Repositories containing high-quality human biospeci-
mens linked with robust and relevant clinical and patholog-
ical information are required for the discovery and validation 
of biomarkers for disease diagnosis, progression and response 
to treatment.24 It is imperative that modern biobanks provide 
the samples needed for discovery projects and ensure require-
ments for ongoing sample collections and the future needs of 
researchers are adequately addressed. Biobanks can work with 
molecular diagnostic laboratories to develop standardised meth-
odologies for the acquisition and storage of samples required 
for new approaches to research such as ‘liquid biopsies’, which 
will ultimately feed into validations required in large prospective 
clinical studies in order to implement liquid biopsy approaches 
for routine clinical practice. This will need to be managed by 
pathologists understanding a large variety of technical aspects, 
ranging from traditional histopathology to the specific work of 
formalin-fixed paraffin-embedded-based DNA and RNA testing.
understanding disease
Both Pathology and Epidemiology aim to elucidate the aetiology 
of disease and the integrated discipline of ‘molecular patholog-
ical epidemiology’ aims to interrogate large sample cohorts from 
epidemiological studies with pathological tools such as IHC and 
TMAs, digital image analysis and high-throughput genomics, 
and link with epidemiological data to reach significant and prac-
tical discoveries.
In recent decades, pathology has witnessed a separation of 
the academic and diagnostic, to the extent that many Pathology 
departments in leading UK teaching hospitals lack any substan-
tial academic activity. Activity to realign the diagnostic and 
research agendas, with specific models to do so, is gaining trac-
tion in the UK. The aim is to draw technological expertise from 
the research environment and to bring a culture of accreditation 
and rigour from diagnostics into research.
models of trAining from A uK perspective
The aim of this document is to propose key points of consid-
erations for training the next generation of pathologists and 
pathology leaders, equipped to deliver healthcare founded 
on morphomolecular diagnoses. But how much molecular 
pathology should a diagnostic pathologist know?
It is a common opinion that the diagnostic histopathologist 
should integrate morphological and molecular information. 
There are two types of integration to consider: diagnostic 
and therapeutic. Diagnostic integration is exemplified by the 
haemato-oncology integrated report, where the result of clon-
ality testing or the presence of a translocation can confirm/
refute a diagnosis of malignancy and provide a clear diagnostic 
certainty. This paradigm is shared by, at least, neuropathology 
and sarcoma/soft tissue pathology.
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Therapeutic integration informs a therapeutic decision. This 
requires very broad knowledge and specific training in molecular 
diagnostics. It requires:
 ► an understanding of the technologies that generated the 
results;
 ► judgement as to whether a specific test is technically satisfac-
tory with the ability to troubleshoot a suboptimal test run;
 ► an understanding of the biological variables that some of 
these tests may bring to the forefront in some cases;
 ► knowledge to manage increasingly complex data 
(ie, bioinformatics);
 ► an understanding of the clinical relevance of test results.
At the moment, pathology training does not deliver these key 
skills and recent attempts to redefine training, while admirable, 
remain too limited. Training programmes that can produce 
pathologists who are also proficient in molecular diagnostics 
need to be developed, although there are significant challenges 
in developing such a programme; training as a competent 
morphologist in most areas of pathology requires a full 5 years 
of training, there are very few molecular pathology centres with 
the capacity to train a steady stream of molecular pathologists 
and the process for modifying a curriculum through the General 
Medical Council (GMC) is complex and lengthy. Here, we 
consider three potential models of delivering a future pathology 
workforce in the UK, taking as a baseline the current training 
structured championed by the Royal College of Pathologists.
model 1
Model 1 would aim to deliver morphomolecular training within 
the current 5-year training timeframe. This would require some 
condensation of the current morphological training, perhaps by 
allowing autopsy or gynae cytopathology to be dropped after stage 
A of training, and delivering a select amount of molecular training. 
This would include molecular pathology lectures in the early stages 
of training, followed by a compulsory 2-month to 3-month molec-
ular attachment and an optional final year training in molecular 
diagnostics. Overall, this represents a meaningful increase in the 
molecular diagnostic training within the existing timeframe and 
structure of general histopathology training. Early training in the 
module has the capacity to be delivered in national/regional blocks, 
and there is the potential for a distance learning component in the 
pre-FRCPath Part 1 phase. This increase in molecular diagnostic 
training would need to be matched by an equally significant exam-
ined component of the FRCPath examinations. This model has 
the advantage of delivering a basic level of molecular pathology 
training to all, with a view to delivering an entire workforce with 
background in molecular diagnostics and the flexibility in stage 
D for suitably interested trainees to develop these skills further. 
Delivering this model of training within the currently existing 
5-year RCPath histopathology training can be done in the appro-
priate centre,25 but nationwide coverage of molecular diagnostics 
may be insufficiently uniform at present to deliver the required 
level of practical molecular pathology training within each UK 
training region.
model 2
Model 2 focuses the delivery of molecular pathology training 
within an optional extension of training to allow an MSc or 
Fellowship in Molecular Pathology to be undertaken before or 
after the FRCPath Part 2. A plethora of Molecular Pathology 
MScs are currently available in the UK through which this addi-
tional training could be delivered to the relevant trainees. As 
the MSc programmes are optional, this could be perceived as an 
additional burden beyond the already demanding requirements 
of histopathology training, however, and if undersubscribed by 
pathology trainees, molecular pathology MSc programmes may 
fail to address the skills gap in molecular pathology. It is crucial 
that if these programmes aim to upskill trainees in molecular 
diagnostic pathology, the projects offered allow development 
of expertise in this area and are not predominantly focused on 
delivering basic science projects, which are used primarily as a 
segue into academic training.
model 3
Model 3 would involve targeted centres, which show they have 
the capacity to train morphomolecular pathologists, to start 
doing so, in programmes accredited by the RCPath, in parallel to 
conventional histopathology training. This would be delivered 
within the context of a modular training programme combining 
morphological and molecular training and would follow an 
approved RCPath template. It is envisaged that while this 
‘hybrid’ morphomolecular training programme is delivered in 
selected centres, the majority would continue with the standard 
training currently being delivered to histopathology trainees. 
These parallel training programmes would potentially reflect 
more accurately the true distinction between general patholo-
gists, who require the balanced general training to report a wide 
range of specimens, completing training the current RCPath 
curriculum (or proposed model 1), and pathologists who prac-
tice monospecialist reporting in centres that also deliver molec-
ular pathology testing being trained through model 3.
Molecular pathology is a vast area that is constantly evolving, 
and it is difficult to have a grasp of every technique and appli-
cation and to learn about techniques in an abstract manner. It 
would therefore be useful to link molecular techniques with the 
context of a pathology subspecialty within a modular training 
programme. This proposal will prove some logistical challenges 
to the relevant training centres and the RCPath, although the 
model would not be unlike the specialist training delivered and 
examined after stage B in head and neck pathology for dentally 
qualified pathologists.
Due to the national strategic importance of genomic medi-
cine within the UK and the already problematic skills gap in 
molecular pathology, such morphomolecular training posts 
should be considered additional to the existing histopathology 
training numbers with a national-level funding model that 
reflects this.
HistopAtHology in 2017: A time to exercise 
responsibility
The discipline of histopathology is at the crossroads. To maintain 
its central role in the evaluation of patients, pathologists will 
need to fully incorporate molecular diagnostics for the under-
standing and characterisation of diseases. If surgical pathologists 
attempt, even passively, to resist this change, this is likely to 
invite others to perform molecular testing of surgical pathology 
samples, moving the central role of tissue-based diagnosis out of 
the field of pathology. Crucially, this will be a poor outcome for 
patients, as morphological and molecular knowledge that needs 
to be integrated will be fragmented into different specialities. 
The strategic position of our discipline at the centre of clinical 
practice may be lost, reducing the importance of histopathology 
as a clinical specialty.
The resulting marginalisation of histopathology in molecular 
medicine will further diminish the current strategic position 
of histopathology at the interface between clinical medi-
cine and biomedical research. Failure to learn the language 
of molecular biology will significantly reduce the input and 
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engagement from histopathologists in tissue-based research 
and their valuable skills will become a more remote resource 
to the biomedical research community, which will ultimately 
impact negatively on the quality of research. In addition, 
molecular diagnostics is a rapidly growing area of medicine, 
moving a budget of many billions of dollars, and appropri-
ately trained molecular pathologists are potentially best placed 
to make appropriate decisions about how these considerable 
investments are made to support optimal, combined morpho-
molecular diagnostics. Histopathologists’ disengagement from 
molecular medicine threatens to exclude our departments 
from significant potential sources of revenue.
The CM-Path group authoring this document has appraised 
the options identified for training the next generation of histo-
pathologists. The group believes that molecular diagnostic 
training should represent a substantial component of the histo-
pathology curriculum in the UK, far beyond what is currently 
delivered, although it is understood that the Royal College of 
Pathologists’ position is that there is little margin to change 
the curriculum at this time.
A revisited version of today’s curriculum, with a significant 
increase in molecular diagnostic training, taking place within the 
current 5-year programme (described in model 1) and increasing 
the time devoted to the theory and practice of molecular 
pathology is certainly the minimum change that the group feels 
is required to properly equip the specialty for future pathology 
practice. Model 2 of training has potential as an interim solu-
tion while more radical change in the curriculum is developed 
although the optional and variable nature of the molecular 
pathology component makes this an inadequate long-term plan 
for upskilling the profession.
Overall, the CM-Path group considers that, in order to secure 
the future of the specialty at the fulcrum of modern medicine, a 
parallel training programme should be implemented. This would 
include one pathway based on current training, which it is envis-
aged the vast majority will follow in the first instance, and an 
alternate option of incorporating in-depth molecular diagnostic 
training over the 5 years by developing modular morphomo-
lecular pathology training programmes (model 3). This parallel 
subspecialist pathway will develop a cohort of highly skilled 
molecular histopathologists both able to strategically secure 
tissue-based molecular diagnostics within our specialty and 
capable of embracing the inevitable increase in morphomolec-
ular diagnostic complexity that each subspecialty will face over 
the coming years.
It is our view that maintaining the status quo will be detri-
mental for both the next generation of pathologists and for 
the specialty as a whole. Whether or not we embrace radical 
change, the eventual future of histopathology will be our 
responsibility. Do we need to nurture molecular pathology as 
much as morphology? How much of the revolution in molec-
ular medicine do we wish to embrace? These are questions 
that our generation can ask itself, though if we do not act 
accordingly, we may be the last generation of pathologists 
able to do so. 
Handling editor Runjan Chetty
funding CM-Path is funded by ten National Cancer Research Institute partner 
organisations (Bloodwise, Breast Cancer Now, Cancer Research UK, the Chief 
Scientist Office (Scotland), the Department of Health (England), Health and Care 
Research Wales (Wales), Health and Social Care (Northern Ireland), the Medical 
Research Council, Prostate Cancer UK and Tenovus Cancer Care).
competing interests None declared.
provenance and peer review Not commissioned; internally peer reviewed.
open Access This is an Open Access article distributed in accordance with the 
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others 
to distribute, remix, adapt and build upon this work, for commercial use, provided 
the original work is properly cited. See: http:// creativecommons. org/ licenses/ by/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
RefeRences
 1 van den Tweel JG, Taylor CR. A brief history of pathology: preface to a forthcoming 
series that highlights milestones in the evolution of pathology as a discipline. 
Virchows Arch 2010;457:3–10.
 2 Gal AA. In search of the origins of modern surgical pathology. Adv Anat Pathol 
2001;8:1–13.
 3 National Cancer Institute. Director’s challenge: toward a molecular classification of 
tumors. Updated 20 Jan 1999. http:// grants. nih. gov/ grants/ guide/ rfa- files/ rfa- ca- 98- 
027. html (accessed 22 May 2017).
 4 Chan JY, Salto-Tellez M. Opinion: molecular Gestalt and modern pathology. Adv Anat 
Pathol 2012;19:425–6.
 5 Salto-Tellez M. A case for integrated morphomolecular diagnostic pathologists.  
Clin Chem 2007;53:1188–90.
 6 Lauwers GY, Black-Schaffer S, Salto-Tellez M. Molecular pathology in contemporary 
diagnostic pathology laboratory: an opinion for the active role of surgical pathologists. 
Am J Surg Pathol 2010;34:115–7.
 7 Siok-Bian N, Lee V, Das K, et al. The relevance of molecular diagnostics in the practice 
of surgical pathology. Expert Opin Med Diagn 2008;2:1401–14.
 8 Salto-Tellez M. Overview of molecular tests and personalized cancer medicine. In: Tan 
D, Lynch HF, eds. Principles of molecular diagnostics and personalized cancer medicine 
(1st ed): Lippincott Williams & Wilkins, 2013.
 9 McCourt CM, Boyle D, James J, et al. Immunohistochemistry in the era of personalised 
medicine. J Clin Pathol 2013;66:58–61.
 10 Maxwell P, Salto-Tellez M. Validation of immunocytochemistry as a morphomolecular 
technique. Cancer Cytopathol 2016;124:540–5.
 11 Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 
breast tumours reveals novel subgroups. Nature 2012;486:346–52.
 12 Rekhtman N, Pietanza MC, Hellmann MD, et al. Next-generation sequencing of 
pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and 
non-small cell carcinoma-like subsets. Clin Cancer Res 2016;22:3618–29.
 13 Liu G, Dong C, Liu L. Integrated multiple "-omics" data reveal subtypes of 
hepatocellular carcinoma. PLoS One 2016;11:e0165457.
 14 Cancer Genome Atlas Research Network. Comprehensive molecular characterization 
of clear cell renal cell carcinoma. Nature 2013;499:43–9.
 15 Salto-Tellez M, Gonzalez de Castro D. Next-generation sequencing: a change of paradigm 
in molecular diagnostic validation. J Pathol 2014;234:5–10.
 16 Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of 
clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 
2014;46:225–33.
 17 Alizadeh AA, Aranda V, Bardelli A, et al. Toward understanding and exploiting tumor 
heterogeneity. Nat Med 2015;21:846–53.
 18 Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-
small-cell lung cancer. N Engl J Med 2017;376:2109–21.
 19 Eccles SA, Aboagye EO, Ali S, et al. Critical research gaps and translational priorities 
for the successful prevention and treatment of breast cancer. Breast Cancer Res 
2013;15:R92.
take home messages
 ► Molecular diagnostics is one of the fastest growing areas of 
medicine.
 ► The involvement of pathology in the modern taxonomy of 
disease has become a matter of general importance for the 
medical and scientific community.
 ► Pathology and pathologists need to rise to the challenge of 
genomic medicine, this will dictate the extent and quality of 
genomic medicine over the next decade.
 ► The National Cancer Research Institute’s CM-Path initiative 
would like to see a change in the postgraduate pathology 
curriculum, to create a new morphomolecular pathology 
specialty in order to deliver high quality molecular diagnostics 
for patient benefit.
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